Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals Inc. (symbol: REGN) is a prominent American biotechnology company headquartered in Westchester County, New York, since its founding in 1988. The core mission of Regeneron is to discover, develop, and commercialize innovative products targeting a range of serious medical conditions. With a diverse portfolio, Regeneron focuses on therapies for eye diseases, cardiovascular conditions, cancer, and inflammatory disorders.
Among its marketed products, Eylea stands out as a treatment for wet age-related macular degeneration and other eye diseases. Praluent is designed to lower LDL cholesterol levels, while Dupixent addresses multiple immunological conditions. In the oncology sector, Libtayo is a key therapy, and Kevzara targets rheumatoid arthritis.
The company is also heavily invested in the development of monoclonal and bispecific antibodies, often in collaboration with Sanofi and other partners. These initiatives include cutting-edge technologies such as RNA interference (RNAi) with Alnylam and CRISPR-based gene editing with Intellia.
Regeneron's recent progress includes significant advancements in its clinical-stage pipeline, which comprises over 35 product candidates. The company's financial health remains robust, supported by strong revenue streams from collaboration with Sanofi and a strategic $3.0 billion share repurchase program authorized by the board.
Latest updates highlight the company's ongoing efforts in gene therapy, particularly in treating genetic deafness and solid tumors. Regeneron's commitment to pioneering genetic medicine and leveraging data insights from the Regeneron Genetics Center® positions it as a leader in the biopharmaceutical industry.
For more information, visit Regeneron Pharmaceuticals.
Rhea-AI Summary
Regeneron Pharmaceuticals and Sanofi announced that the FDA has updated the label for Dupixent in atopic dermatitis, adding efficacy and safety data for patients aged 12 years and older with uncontrolled moderate-to-severe hand and/or foot involvement. The Phase 3 trial showed significant improvement in skin clarity and itch reduction for patients treated with Dupixent compared to placebo. The label update is based on data from the Phase 3 LIBERTY-AD-HAFT trial, with patients treated with Dupixent experiencing a 40% achievement of clear or almost clear skin on hands and feet compared to 17% with placebo, as well as a 52% reduction in itch compared to 14% with placebo. The safety profile of Dupixent remains consistent with known data, with common adverse events including injection site reactions, conjunctivitis, and others.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
-
Rhea-AI Summary
Medison Pharma (Medison) (NASDAQ: REGN) has announced an exclusive multi-national agreement with Regeneron Ireland DAC, a subsidiary of Regeneron Pharmaceuticals, to commercialize Libtayo (cemiplimab) in select European markets and additional markets worldwide. Libtayo is a leading PD-1 inhibitor approved for the treatment of certain patients with cutaneous squamous cell carcinoma, advanced basal cell carcinoma, advanced non-small cell lung cancer, and advanced cervical cancer in more than two dozen countries. The agreement aims to continue patient access to this important therapy and facilitate a seamless transition of commercialization activities to Medison during the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will report its Q4 and full year 2023 financial and operating results on February 2, 2024. The conference call and webcast will be held at 8:30 AM Eastern Time on the same day. Participants can access the live webcast on the company's website or register in advance for the telephone conference call. A replay and transcript will be available on the website for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the 'Investors & Media' page of Regeneron's website. A replay and transcript of the webcast will be archived on the Company's website for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has been included on the Dow Jones Sustainability World Index (DJSI World) for the fifth consecutive year, alongside its fourth consecutive inclusion on the Dow Jones Sustainability North America Index (DJSI North America). Regeneron's dedication to sustainability is reflected in its consistent rankings, acknowledging the top 10 percent of the world's most sustainable companies in each industry. Regeneron stands proud as one of only five biotechnology firms globally to make the list, ranking among the top 2 percent. The company's improvement areas in this year’s assessment were climate strategy, labor practice indicators, and tax strategy. Regeneron's commitment to corporate responsibility is further highlighted by its impressive performance across various top ESG ratings and rankings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) presented positive data for odronextamab in patients with relapsed/refractory follicular lymphoma (FL) from a pivotal Phase 2 trial (ELM-2) at the 65th American Society of Hematology (ASH) Annual Meeting. The data demonstrated an 80% objective response rate and a 73% complete response (CR), with a 23-month median duration of response and 24-month median duration of CR. Odronextamab is an investigational CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced Phase 2 primary analysis results for odronextamab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) at the 65th American Society of Hematology (ASH) Annual Meeting. The data showed a 52% objective response rate (ORR) and 31% complete response (CR) in the pivotal Phase 2 trial, with additional positive results from the Phase 1 trial. The primary analysis demonstrated impressive response rates, including in high-risk subgroups, and the potential treatment option for patients with this aggressive blood cancer. Odronextamab is currently under regulatory review for the treatment of R/R DLBCL and R/R FL by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the primary endpoint analysis from the pivotal trial investigating linvoseltamab demonstrated high rates of deep and durable responses in patients with relapsed/refractory multiple myeloma. At a median duration of follow-up of 11 months, an objective response rate of 71% was observed, with 46% achieving a complete response or better. The regimen had a convenient, response-adapted administration schedule that enabled deep responders to go from every two-week to every four-week dosing. All patients treated with 200 mg experienced an adverse event, including 85% who experienced Grade ≥3 adverse events. Deaths due to treatment-emergent AEs on-treatment or within 30 days post last dose occurred in 14 patients (12%).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (REGN) presented encouraging Phase 1 dose-escalation data for REGN5668 (MUC16xCD28) in combination with Libtayo (cemiplimab) at the ESMO IO Congress 2023. Initial results show early clinical activity in patients with recurrent ovarian cancer, with a 21% stable disease rate and a 59% target lesion reduction from baseline in one patient. The combination demonstrated an acceptable safety profile with fatigue, nausea, and pain as the most common treatment-related adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a conference call and webcast on December 14, 2023, to provide an update on its hematology portfolio. This follows data updates presented at the 65th ASH Annual Meeting and Exposition. The webcast can be accessed on the company's website, and a replay will be available for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
FAQ
What is the current stock price of Regeneron Pharmaceuticals (REGN)?
The current stock price of Regeneron Pharmaceuticals (REGN) is $694.64 as of January 23, 2025.
What is the market cap of Regeneron Pharmaceuticals (REGN)?
The market cap of Regeneron Pharmaceuticals (REGN) is approximately 74.8B.
What types of diseases does Regeneron Pharmaceuticals focus on?
Regeneron focuses on eye diseases, cardiovascular conditions, cancer, and inflammatory disorders.
What are some of Regeneron's key products?
Key products include Eylea for eye diseases, Praluent for lowering LDL cholesterol, Dupixent for immunology, Libtayo for oncology, and Kevzara for rheumatoid arthritis.
Who are some of Regeneron's notable collaborators?
Regeneron collaborates with Sanofi, Alnylam, and Intellia on various projects, including monoclonal and bispecific antibodies, RNAi, and CRISPR-based gene editing.
What recent financial steps has Regeneron taken?
Regeneron has initiated a $3.0 billion share repurchase program and reported strong financial performance in the first quarter of 2024.
How does Regeneron leverage genetic medicine?
Regeneron utilizes data-powered insights from the Regeneron Genetics Center® and employs proprietary technologies like VelociSuite® to advance drug development.
What is the significance of Eylea in Regeneron's product portfolio?
Eylea is a crucial product for treating wet age-related macular degeneration and other eye diseases, contributing significantly to Regeneron's revenue.
What advancements has Regeneron made in gene therapy?
Regeneron is progressing in gene therapy for genetic deafness and solid tumors, showcasing promising early results in clinical trials.
What is Dupixent used for?
Dupixent is used in treating various immunological conditions and has shown significant growth since its launch, treating over 850,000 patients.
What technologies does Regeneron use for drug development?
Regeneron uses proprietary technologies such as VelociSuite®, which includes platforms for producing optimized human antibodies and bispecific antibodies.
How does Regeneron contribute to scientific discovery?
Regeneron pushes the boundaries of scientific discovery with pioneering genetic medicine platforms and data insights, aiming to develop transformative therapies.
Regeneron Pharmaceuticals Inc
Nasdaq:REGN
REGN Rankings
REGN Stock Data
74.82B
106.22M
1.57%
90.64%
1.71%
Biotechnology
Pharmaceutical Preparations
United States of America
TARRYTOWN